Carlos Gallardo

1.5k total citations
21 papers, 324 citations indexed

About

Carlos Gallardo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Carlos Gallardo has authored 21 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 9 papers in Surgery. Recurrent topics in Carlos Gallardo's work include Cancer Immunotherapy and Biomarkers (13 papers), Gastric Cancer Management and Outcomes (9 papers) and Esophageal Cancer Research and Treatment (9 papers). Carlos Gallardo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Gastric Cancer Management and Outcomes (9 papers) and Esophageal Cancer Research and Treatment (9 papers). Carlos Gallardo collaborates with scholars based in Chile, Japan and United States. Carlos Gallardo's co-authors include Marco Torregroza Otero, Carlos H. Barrios, Norikazu Masuda, Mastura Md Yusof, Sherene Loi, Hope S. Rugo, Erhan Gökmen, David W. Cescon, Javier Cortés and Oleg Lipatov and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Carlos Gallardo

20 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carlos Gallardo Chile 9 260 164 65 60 52 21 324
Delia De Lisi Italy 10 101 0.4× 127 0.8× 54 0.8× 24 0.4× 48 0.9× 18 262
Y. Kakeji Japan 10 109 0.4× 91 0.6× 23 0.4× 88 1.5× 115 2.2× 18 317
Rebeca Mondéjar Spain 8 137 0.5× 96 0.6× 86 1.3× 14 0.2× 32 0.6× 17 241
Inês Carvalho Portugal 5 89 0.3× 51 0.3× 49 0.8× 17 0.3× 24 0.5× 16 280
Tamara Saurí Spain 9 107 0.4× 45 0.3× 41 0.6× 10 0.2× 49 0.9× 30 226
Yung‐Yeh Su Taiwan 10 144 0.6× 62 0.4× 42 0.6× 6 0.1× 85 1.6× 31 207
Amy Gursky United States 5 82 0.3× 53 0.3× 47 0.7× 26 0.4× 67 1.3× 5 208
Hélène Vanacker France 9 87 0.3× 99 0.6× 29 0.4× 16 0.3× 13 0.3× 33 226
Carmen Salvador Coloma Spain 9 116 0.4× 82 0.5× 71 1.1× 24 0.4× 21 0.4× 32 248
Toshihiko Matsumoto Japan 10 232 0.9× 181 1.1× 30 0.5× 7 0.1× 97 1.9× 50 350

Countries citing papers authored by Carlos Gallardo

Since Specialization
Citations

This map shows the geographic impact of Carlos Gallardo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Gallardo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Gallardo more than expected).

Fields of papers citing papers by Carlos Gallardo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Gallardo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Gallardo. The network helps show where Carlos Gallardo may publish in the future.

Co-authorship network of co-authors of Carlos Gallardo

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Gallardo. A scholar is included among the top collaborators of Carlos Gallardo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Gallardo. Carlos Gallardo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Shitara, Kohei, Markus Moehler, Jaffer A. Ajani, et al.. (2024). Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.. Journal of Clinical Oncology. 42(16_suppl). 4040–4040. 3 indexed citations
3.
4.
Cescon, David W., Peter Schmid, Hope S. Rugo, et al.. (2023). Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. JNCI Journal of the National Cancer Institute. 116(5). 717–727. 7 indexed citations
5.
Janjigian, Yelena Y., Kohei Shitara, Markus Moehler, et al.. (2023). Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.. Journal of Clinical Oncology. 41(4_suppl). 291–291. 22 indexed citations
6.
Janjigian, Yelena Y., Kohei Shitara, Markus Moehler, et al.. (2023). Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.. Journal of Clinical Oncology. 41(16_suppl). 4025–4025. 3 indexed citations
7.
8.
9.
Cortés, Javier, David W. Cescon, Hope S. Rugo, et al.. (2021). LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Annals of Oncology. 32. S1289–S1290. 37 indexed citations
10.
11.
12.
Villanueva-Rivera, Luis J., Jean M. Butte, Pamela Salman, et al.. (2021). Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety. ecancermedicalscience. 15. 1168–1168. 10 indexed citations
13.
Jongsma, Hannah E., Juan Undurraga, Nicolás Crossley, et al.. (2020). The incidence of non-affective psychotic disorders in Chile between 2005 and 2018: results from a national register of over 30 000 cases. Psychological Medicine. 52(5). 914–923. 8 indexed citations
14.
Gallardo, Carlos, et al.. (2020). Uso de cannabis en jóvenes hospitalizados por un primer episodio de psicosis: un estudio caso-control. Revista médica de Chile. 148(11). 1606–1613. 2 indexed citations
15.
16.
Cortés, Javier, David W. Cescon, Hope S. Rugo, et al.. (2020). KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.. Journal of Clinical Oncology. 38(15_suppl). 1000–1000. 137 indexed citations
17.
Castañeda, Carmen, et al.. (2019). High prevalence of metabolic alterations in Latin American patients at initial stages of psychosis. Early Intervention in Psychiatry. 13(6). 1382–1388. 4 indexed citations
18.
Caglevic, Christian, et al.. (2019). Triple-negative breast cancer: the reality in Chile and in Latin America. ecancermedicalscience. 13. 893–893. 11 indexed citations
19.
Villanueva-Rivera, Luis J., Olga Barajas, Carlos Gallardo, et al.. (2018). Complete preoperative chemotherapy regimen FLOT: Evaluating the safety and histopathologic results in gastric cancer (GC).. Journal of Clinical Oncology. 36(15_suppl). e16016–e16016.
20.
Undurraga, Juan, et al.. (2015). Implementing Psychosocial Evidence-Based Practices in Mental Health: Are We Moving in the Right Direction?. Frontiers in Psychiatry. 6. 51–51. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Delia De Lisi Breakdown of academic impact, for papers by Y. Kakeji Breakdown of academic impact, for papers by Rebeca Mondéjar Breakdown of academic impact, for papers by Inês Carvalho Breakdown of academic impact, for papers by Tamara Saurí Breakdown of academic impact, for papers by Yung‐Yeh Su Breakdown of academic impact, for papers by Amy Gursky Breakdown of academic impact, for papers by Hélène Vanacker Breakdown of academic impact, for papers by Carmen Salvador Coloma Breakdown of academic impact, for papers by Toshihiko Matsumoto
Rankless by CCL
2026